Home About us Current issue Back issues Submission Instructions Advertise Contact Login   

Search Article 
  
Advanced search 
 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 5564 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 

ARTICLE Table of Contents   
Year : 2000  |  Volume : 11  |  Issue : 3  |  Page : 325-333
Ways of Treating IgA Nephropathies


c/o 81 Gloucester Avenue,Grimsby, England DN 34 5 BU, United Kingdom

Correspondence Address:
E Nigel Wardle
c/o 81 Gloucester Avenue, Grimsby, England DN34 5BU
United Kingdom
Login to access the Email id


PMID: 18209324

Rights and Permissions

Summary: Treatment options for IgA nephropathy (IgAN) must take into consideration the pathophysiology, namely the role of eicosanoids, angiotensin II and monocyte­macrophages releasing reactive oxygen species (ROS). Angiotensin converting enzyme inhibitors and early corticosteroid usage are prime therapies. Tonsillectomy should be considered. Other components of a therapeutic cocktail could be; (a) thromboxane antogonist, (b) leukotriene antagonist, (c) platelet activating factor antagonist, (d) an anti­oxidant and (e) an anti-fibrotic agent like pentoxyfylline. In the new millenium, there will be focus on anti-proliferative measures like platelets dependent growth factor aptamers. For unusual cases with rapid progression, the use of FK-506 or mycophenolate mofetil can be considered.


[FULL TEXT] [PDF]*
Print this article  Email this article
    

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed4229    
    Printed83    
    Emailed0    
    PDF Downloaded491    
    Comments [Add]    

Recommend this journal